➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Harvard Business School
Mallinckrodt
AstraZeneca
Baxter

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,801,881


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,801,881
Title:Use of inhibitors of bruton's tyrosine kinase (BTK)
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s): Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (Incline Village, NV), Mody; Tarak D. (Sunnyvale, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:14/091,196
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,801,881
Patent Claims: 1. A method for treating chronic lymphocytic leukemia in an individual who has failed at least one prior therapy for chronic lymphocytic leukemia comprising administering to the individual once per day about 420 mg of an oral dose of an inhibitor of Bruton's tyrosine kinase (Btk) having the structure: ##STR00047##

2. The method of claim 1, wherein the oral dose is a capsule.

3. A method for treating relapsed or refractory chronic lymphocytic leukemia in an individual comprising administering to the individual in need thereof once per day about 420 mg of an oral dose of an inhibitor of Bruton's tyrosine kinase (Btk) having the structure: ##STR00048##

4. The method of claim 3, wherein the oral dose is a capsule.

5. The method of claim 1, wherein, following administration of the inhibitor, the individual achieves a stable disease, a partial response, or a complete response.

6. The method of claim 1, wherein, following administration of the inhibitor, the individual achieves a partial response or a complete response.

7. The method of claim 1, wherein, following administration of the inhibitor, the individual achieves a complete response.

8. The method of claim 1, wherein, following administration of the inhibitor, the individual does not experience a progressive disease.

9. The method of claim 1, wherein the individual has nucleic acid deletion in chromosome 17.

10. The method of claim 9, wherein the deletion is in 17p.

11. The method of claim 10, wherein the deletion is in 17p13.

12. The method of claim 3, wherein, following administration of the inhibitor, the individual achieves a stable disease, a partial response, or a complete response.

13. The method of claim 3, wherein, following administration of the inhibitor, the individual achieves a partial response or a complete response.

14. The method of claim 3, wherein, following administration of the inhibitor, the individual achieves a complete response.

15. The method of claim 3, wherein, following administration of the inhibitor, the individual does not experience a progressive disease.

16. The method of claim 3, wherein the individual has nucleic acid deletion in chromosome 17.

17. The method of claim 16, wherein the deletion is in 17p.

18. The method of claim 17, wherein the deletion is in 17p13.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Harvard Business School
Dow
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.